A method for using plant-derived small interfering ribonucleic acid mir162a as antisense therapy for osteosarcoma
Patent Information
- Application Number
- RU2023103325
- Authority / Receiving Office
- RU · RU
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-02-14
- Publication Date
- 2026-06-30
Claims
1. A method for using small interfering ribonucleic acid as an antisense therapy for tumor diseases, comprising at least one nucleotide sequence, characterized in that the plant small interfering ribonucleic acid mir162a is used as the antisense sequence.
2. The method according to claim 1, characterized in that the small interfering ribonucleic acid mir162a with antisense SEQ ID NO: 1 and sense SEQ ID NO: 2, according to the sequence listing.
3. The method according to paragraph 1, characterized in that it is intended for antisense therapy of osteosarcoma ICD10 C40-C41.
4. The method according to claim 1, characterized in that a pharmaceutical composition for the treatment of malignant tumors is used, containing the molecule according to claim 2 and a pharmaceutically acceptable carrier.
5. The method according to claim 4, characterized in that the pharmaceutically acceptable carrier may be a lipid molecule or a liposome.
6. The method according to claim 4, characterized in that the pharmaceutical composition contains 45 pmol of the antisense sequence of the small interfering ribonucleic acid mir162a according to claim 2.
7. The method according to claim 4, characterized in that the pharmaceutical composition contains 45 pmol of the sense sequence of the small interfering ribonucleic acid mir162a according to claim 2.
8. The method according to claim 4, characterized in that the pharmaceutical composition contains 9 μl of a pharmaceutically acceptable carrier according to claim 4 and 250 μl of an isotonic solution.
9. The method according to paragraphs 6-8, characterized in that the use of the medicinal product is used to treat malignant tumors by knocking down the mTOR gene, wherein the method comprises administering to the subject the composition according to paragraphs 6-8.
10. The method according to paragraphs 6-8, characterized in that the use of the medicinal product is used to treat malignant tumors in a subject in need thereof.